DGKZ

Across TCGA pan-cancer cohorts, DGKZ mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DGKZ data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DGKZ mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DGKZ expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where DGKZ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.933	0.440	.007	24	view →
LUAD	OS	Quartile	III,IV	0.264	0.789	.001	20	view →
HNSC	DFS	Tertile	III,IV	1.000	0.896	.011	13	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.355	.012	7	view →
LSCC	OS	Tertile	III,IV	0.721	0.348	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DGKZ–PDAC (DFS)

Open the PDAC breakdown →